Breaking Finance News

Zacks Investment Research downgraded Omeros Corporation (NASDAQ:OMER) to Sell in a report released today.

Yesterday Omeros Corporation (NASDAQ:OMER) traded -5.90% lower at $8.61. The company’s 50-day moving average is $10.88 and its 200-day moving average is $11.84. The last stock close price is down -27.29% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 471,244 shares of the stock were exchanged, up from an average trading volume of 343,863

Zacks Investment Research has downgraded Omeros Corporation (NASDAQ:OMER) to Sell in a report released on 10/12/2016.

Previously on 8/10/2016, Maxim Group reported about Omeros Corporation (NASDAQ:OMER) lowered the target price from $30.00 to $19.00. At the time, this indicated a possible upside of 0.42%.

See Chart Below

Omeros Corporation (NASDAQ:OMER)

Omeros Corporation has a 52 week low of $8.55 and a 52 week high of $16.80 The company’s market cap is currently $0.

In addition to Zacks Investment Research reporting its target price, a total of 6 firms have reported on the stock. The consensus target price is $42.33 with 3 firms rating the stock a strong buy, 3 firms rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About Omeros Corporation (NASDAQ:OMER)

Omeros Corporation is a biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company's marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens replacement. Its clinical programs include Mannan-binding lectin-associated serine protease-2 (MASP-2) (OMS721)-Lectin Pathway Disorders; PDE10 (OMS824)-CNS Disorders; peroxisome proliferator-activated receptor gamma (PPARy) (OMS405)-Addiction, and OMS201-Urology. Its preclinical programs include phosphodiesterase 7 (PDE7) (OMS527), Plasmin (OMS616), MASP-3 (OMS906)-Alternative Pathway Disorders, GPR17-CNS Disorders, GPR101-Metabolic Disorders, GPR151-CNS Disorders, GPR161-Cancer, GPR174-Immune Disorders, GPR183-Skeletal and Infectious Diseases, GPCR Platform and Antibody Platform.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.